JP5540101B2 - ベンゾオキサゼピンｐｉ３ｋ阻害剤化合物及び使用方法 - Google Patents

ベンゾオキサゼピンｐｉ３ｋ阻害剤化合物及び使用方法 Download PDF

Info

Publication number
JP5540101B2
JP5540101B2 JP2012530282A JP2012530282A JP5540101B2 JP 5540101 B2 JP5540101 B2 JP 5540101B2 JP 2012530282 A JP2012530282 A JP 2012530282A JP 2012530282 A JP2012530282 A JP 2012530282A JP 5540101 B2 JP5540101 B2 JP 5540101B2
Authority
JP
Japan
Prior art keywords
triazol
isopropyl
dihydrobenzo
oxazepine
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012530282A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505917A5 (enExample
JP2013505917A (ja
Inventor
二コール ブラキエール，
スティーヴン ドゥ，
ダネット ダドリー，
エイドリアン ジェイ． フォークス，
ロバート ヒールド，
ティモシー ヘフロン，
マーク ジョーンズ，
アレクサンドル コレスニコフ，
チュディ ンドゥバク，
アラン ジー． オリヴェロ，
スティーヴン プライス，
スティーヴン ステイベン，
ラン ワン，
Original Assignee
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43037239&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5540101(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2013505917A publication Critical patent/JP2013505917A/ja
Publication of JP2013505917A5 publication Critical patent/JP2013505917A5/ja
Application granted granted Critical
Publication of JP5540101B2 publication Critical patent/JP5540101B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2012530282A 2009-09-28 2010-09-27 ベンゾオキサゼピンｐｉ３ｋ阻害剤化合物及び使用方法 Active JP5540101B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24638109P 2009-09-28 2009-09-28
US61/246,381 2009-09-28
US33068510P 2010-05-03 2010-05-03
US61/330,685 2010-05-03
PCT/EP2010/064208 WO2011036280A1 (en) 2009-09-28 2010-09-27 Benzoxazepin pi3k inhibitor compounds and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013228826A Division JP5625101B2 (ja) 2009-09-28 2013-11-01 ベンゾオキサゼピンｐｉ３ｋ阻害剤化合物及び使用方法

Publications (3)

Publication Number Publication Date
JP2013505917A JP2013505917A (ja) 2013-02-21
JP2013505917A5 JP2013505917A5 (enExample) 2013-12-19
JP5540101B2 true JP5540101B2 (ja) 2014-07-02

Family

ID=43037239

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012530282A Active JP5540101B2 (ja) 2009-09-28 2010-09-27 ベンゾオキサゼピンｐｉ３ｋ阻害剤化合物及び使用方法
JP2013228826A Active JP5625101B2 (ja) 2009-09-28 2013-11-01 ベンゾオキサゼピンｐｉ３ｋ阻害剤化合物及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013228826A Active JP5625101B2 (ja) 2009-09-28 2013-11-01 ベンゾオキサゼピンｐｉ３ｋ阻害剤化合物及び使用方法

Country Status (31)

Country Link
US (7) US8242104B2 (enExample)
EP (3) EP2483278B1 (enExample)
JP (2) JP5540101B2 (enExample)
KR (1) KR101428346B1 (enExample)
CN (2) CN102762576B (enExample)
AR (1) AR078187A1 (enExample)
AU (1) AU2010299816C1 (enExample)
BR (1) BR112012006807A2 (enExample)
CA (1) CA2772691C (enExample)
CL (1) CL2012000754A1 (enExample)
CO (1) CO6491026A2 (enExample)
CR (1) CR20120121A (enExample)
DK (1) DK2483278T3 (enExample)
EC (1) ECSP12011755A (enExample)
ES (2) ES2570569T3 (enExample)
HR (1) HRP20140229T1 (enExample)
IL (2) IL217558A (enExample)
MA (1) MA33531B1 (enExample)
MX (1) MX2012003591A (enExample)
MY (2) MY160064A (enExample)
NZ (1) NZ597833A (enExample)
PE (1) PE20121025A1 (enExample)
PL (1) PL2483278T3 (enExample)
PT (1) PT2483278E (enExample)
RS (1) RS53164B (enExample)
RU (2) RU2654068C1 (enExample)
SG (1) SG10201405049RA (enExample)
SI (1) SI2483278T1 (enExample)
TW (1) TWI423980B (enExample)
WO (1) WO2011036280A1 (enExample)
ZA (1) ZA201202199B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509611A (ja) * 2011-03-21 2014-04-21 エフ．ホフマン−ラ ロシュ アーゲー ＰＩ３Ｋｐ１１０δに選択的なベンゾオキサゼピン化合物及び使用方法

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2464645T1 (sl) 2009-07-27 2017-10-30 Gilead Sciences, Inc. Zlite heterociklične spojine kot ionsko kanalni modulatorji
JP5546636B2 (ja) 2009-09-28 2014-07-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾキセピンｐｉ３ｋ阻害剤化合物及び使用方法
PL2483278T3 (pl) * 2009-09-28 2014-05-30 Hoffmann La Roche Związki benzoksazepinowe stanowiące inhibitor pi3k i ich zastosowanie w leczeniu nowotworu
MX2012015096A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Compuestos heterociclicos fusionados como moduladores del canal ion.
NZ716420A (en) 2011-05-10 2017-05-26 Gilead Sciences Inc Fused heterocyclic compounds as sodium channel modulators
WO2012156379A1 (en) 2011-05-13 2012-11-22 Universität Zürich PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING
NO3175985T3 (enExample) * 2011-07-01 2018-04-28
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
BR112014019209A2 (pt) * 2012-02-17 2017-07-04 Hoffmann La Roche compostos tricíclicos e métodos de uso para os mesmos
EP2858666B1 (en) * 2012-06-08 2019-09-04 F.Hoffmann-La Roche Ag Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
KR102427777B1 (ko) 2012-06-26 2022-08-01 델 마 파마슈티컬스 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
CN102775395A (zh) * 2012-07-12 2012-11-14 江苏七洲绿色化工股份有限公司 一种丙环唑的制备方法及丙环唑中间体
IN2015DN00659A (enExample) * 2012-08-07 2015-06-26 Janssen Pharmaceutica Nv
SG10201706760YA (en) 2013-03-13 2017-10-30 Hoffmann La Roche Process for making benzoxazepin compounds
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
US9266903B2 (en) * 2013-12-16 2016-02-23 Genentech, Inc. Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazole-5-yl)-5,6-dihydrobenzo[F]imidazo [1,2-D][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof
RU2016137122A (ru) 2014-03-13 2018-04-18 Ф. Хоффманн-Ля Рош Аг Терапевтические комбинации с модуляторами рецепторов эстрогена
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
PL3292116T3 (pl) 2015-02-02 2022-02-21 Valo Health, Inc. 3-arylo-4-amidobicykliczne kwasy [4,5,0]hydroksamowe jako inhibitory hdac
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
US10351576B2 (en) * 2015-04-30 2019-07-16 Novartis Ag Fused tricyclic pyrazole derivatives useful for farnesoid X receptors
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
CN107635560A (zh) 2015-06-29 2018-01-26 豪夫迈·罗氏有限公司 用他塞利昔布进行治疗的方法
AU2016287463B2 (en) * 2015-07-02 2020-07-02 F. Hoffmann-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
JP6522807B2 (ja) * 2015-07-02 2019-05-29 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
US10065970B2 (en) 2015-09-08 2018-09-04 Genentech, Inc. Tricyclic PI3K inhibitor compounds and methods of use
US9721369B2 (en) * 2015-09-15 2017-08-01 Facebook, Inc. Systems and methods for utilizing multiple map portions from multiple map data sources
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN109982999A (zh) 2016-09-29 2019-07-05 拜耳作物科学股份公司 新的5-取代的咪唑基甲基衍生物
HRP20230948T1 (hr) * 2016-12-15 2023-11-24 F. Hoffmann - La Roche Ag Postupak za proizvodnju (s)-2-((2-((s)-4-(difluorometil)-2-oksooksazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2−d][1,4]oksazepin-9-il)amino) propanamida
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
EP3615541B1 (en) * 2017-04-28 2025-03-19 F. Hoffmann-La Roche AG Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
IL274027B2 (en) * 2017-10-26 2023-12-01 Xynomic Pharmaceuticals Inc Crystalline salts of a b-raf kinase inhibitor
MX2020012347A (es) * 2018-05-30 2021-01-29 Jiangsu Hansoh Pharmaceutical Group Co Ltd Inhibidor que contiene derivado triciclico, metodo de preparacion del mismo y aplicacion del mismo.
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途
WO2021088839A1 (zh) * 2019-11-04 2021-05-14 贝达药业股份有限公司 咪唑烷酮类化合物及其制备方法与应用
WO2021088845A1 (zh) * 2019-11-04 2021-05-14 贝达药业股份有限公司 咪唑烷酮类化合物及其制备方法与应用
WO2021104146A1 (zh) * 2019-11-25 2021-06-03 上海翰森生物医药科技有限公司 含三并环类衍生物的盐或晶型及其药物组合物
CA3217763A1 (en) * 2021-05-03 2022-11-10 Bin Liu Tricyclic ubiquitin specific protease 1 inhibitor and use thereof
AU2022275275A1 (en) * 2021-05-13 2023-12-14 Betta Pharmaceuticals Co., Ltd Polymorph of imidazolidinone compound, preparation method therefor and use thereof
WO2022251567A1 (en) 2021-05-28 2022-12-01 Genentech, Inc. Process for the preparation of benzoxazepin oxazolidinone compounds
CN120202205A (zh) * 2022-11-17 2025-06-24 微境生物医药科技(上海)有限公司 三并环类PI3Kα抑制剂及其制备方法和医药用途
CN116003280B (zh) * 2022-12-30 2024-11-19 合肥工业大学 一种芳基甲酰胺类化合物的光化学合成方法
WO2025082533A1 (zh) * 2023-10-21 2025-04-24 上海轶诺药业有限公司 一种稠环化合物及其制备和应用
WO2025237374A1 (zh) * 2024-05-16 2025-11-20 微境生物医药科技(上海)有限公司 PI3Kα抑制剂及其制备方法和医药用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB8504702D0 (en) 1985-02-23 1985-03-27 Zyma Sa Tricyclic compounds
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
ES2102195T3 (es) 1992-12-28 1997-07-16 Eisai Co Ltd Derivados heterociclicos de acido carbonico que se fijan en receptores de retinoides.
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US5985799A (en) 1995-11-17 1999-11-16 E.I. Du Pont De Nemours And Company Tricyclic herbicidal heterocycles
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
DE19908533A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908535A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908538A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908537A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
AU2001246494A1 (en) 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
MXPA03006950A (es) 2001-02-02 2003-11-18 Schering Corp Ciclobuteno-1,2-dionas 3,4-disustituidas como antagonistas de receptor de quimiocina cxc.
TWI232863B (en) * 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
US20040082602A1 (en) 2002-07-19 2004-04-29 Hagen Timothy J. Substituted thiophene carboxamide compounds for the treatment of inflammation
WO2004069245A1 (en) * 2003-02-07 2004-08-19 Warner-Lambert Company Llc Oxazolidinone derivates n-substituted by a tricyclic ring, for use as antibacterial agents
TW200510356A (en) * 2003-08-01 2005-03-16 Takeda Chemical Industries Ltd Benzoxaepine compounds
US20050239767A1 (en) 2003-10-28 2005-10-27 Chan Michael K Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
EP1765830B1 (en) * 2004-07-01 2010-09-22 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
CN101048418A (zh) 2004-10-07 2007-10-03 贝林格尔·英格海姆国际有限公司 Pi3－激酶
AU2006302415B2 (en) 2005-10-07 2012-09-13 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US20070238718A1 (en) * 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
GB0610866D0 (en) * 2006-06-02 2006-07-12 Hammersmith Imanet Ltd Novel in vivo imaging compounds
CA2659280A1 (en) * 2006-07-28 2008-01-31 Alcan Packaging Flexible France Coextruded film with polylactic acid (pla) and ethylene vinyl acetate (eva)
ES2614931T3 (es) 2006-08-04 2017-06-02 Beth Israel Deaconess Medical Center Inhibidores de la piruvato cinasa y métodos de tratamiento de enfermedad
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
KR20150090281A (ko) * 2006-12-29 2015-08-05 아비에 도이치란트 게엠베하 운트 콤파니 카게 카복스아미드 화합물 및 칼페인 억제제로서의 이의 용도
WO2009038795A2 (en) 2007-09-19 2009-03-26 The Regents Of The University Of California Positron emission tomography probes for imaging immune activation and selected cancers
TWI443102B (zh) * 2008-03-31 2014-07-01 Genentech Inc 苯并哌喃及苯并氧呯ｐｉ３ｋ抑制劑化合物及其使用方法
WO2010043676A1 (en) * 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor
PL2483278T3 (pl) * 2009-09-28 2014-05-30 Hoffmann La Roche Związki benzoksazepinowe stanowiące inhibitor pi3k i ich zastosowanie w leczeniu nowotworu
JP5546636B2 (ja) * 2009-09-28 2014-07-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾキセピンｐｉ３ｋ阻害剤化合物及び使用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509611A (ja) * 2011-03-21 2014-04-21 エフ．ホフマン−ラ ロシュ アーゲー ＰＩ３Ｋｐ１１０δに選択的なベンゾオキサゼピン化合物及び使用方法

Also Published As

Publication number Publication date
US8785626B2 (en) 2014-07-22
CR20120121A (es) 2012-06-01
MY184074A (en) 2021-03-17
ES2570569T3 (es) 2016-05-19
EP2711368B1 (en) 2016-03-23
US8343955B2 (en) 2013-01-01
IL217558A0 (en) 2012-02-29
PT2483278E (pt) 2014-03-05
US8586574B2 (en) 2013-11-19
US8242104B2 (en) 2012-08-14
KR101428346B1 (ko) 2014-08-07
AU2010299816C1 (en) 2018-02-01
IL217558A (en) 2015-06-30
JP2013505917A (ja) 2013-02-21
HK1211929A1 (en) 2016-06-03
US20110076292A1 (en) 2011-03-31
ECSP12011755A (es) 2012-05-30
US9546178B2 (en) 2017-01-17
CN102762576A (zh) 2012-10-31
CN104744491B (zh) 2017-07-11
PL2483278T3 (pl) 2014-05-30
DK2483278T3 (da) 2014-01-13
KR20120065431A (ko) 2012-06-20
SI2483278T1 (sl) 2014-03-31
MY160064A (en) 2017-02-15
CN102762576B (zh) 2015-04-22
IL239081A0 (en) 2015-07-30
HRP20140229T1 (hr) 2014-04-11
RU2654068C1 (ru) 2018-05-16
RS53164B (sr) 2014-06-30
US20140058098A1 (en) 2014-02-27
AU2010299816A1 (en) 2012-02-02
US20170081341A1 (en) 2017-03-23
NZ597833A (en) 2014-01-31
WO2011036280A1 (en) 2011-03-31
JP5625101B2 (ja) 2014-11-12
CA2772691A1 (en) 2011-03-31
RU2600927C2 (ru) 2016-10-27
CO6491026A2 (es) 2012-07-31
RU2012117398A (ru) 2013-11-10
MA33531B1 (fr) 2012-08-01
US9198918B2 (en) 2015-12-01
CN104744491A (zh) 2015-07-01
US20160052933A1 (en) 2016-02-25
US20140288047A1 (en) 2014-09-25
PE20121025A1 (es) 2012-08-06
HK1174629A1 (en) 2013-06-14
EP2845592A1 (en) 2015-03-11
SG10201405049RA (en) 2014-10-30
IL239081B (en) 2018-05-31
US9670228B2 (en) 2017-06-06
ES2444779T3 (es) 2014-02-26
EP2483278B1 (en) 2013-12-25
CA2772691C (en) 2017-10-03
EP2711368A1 (en) 2014-03-26
US20130079331A1 (en) 2013-03-28
EP2483278A1 (en) 2012-08-08
AR078187A1 (es) 2011-10-19
JP2014070075A (ja) 2014-04-21
US20120244149A1 (en) 2012-09-27
TW201127844A (en) 2011-08-16
MX2012003591A (es) 2012-04-19
CL2012000754A1 (es) 2012-09-07
TWI423980B (zh) 2014-01-21
AU2010299816B2 (en) 2015-11-12
ZA201202199B (en) 2013-01-30
BR112012006807A2 (pt) 2020-11-03

Similar Documents

Publication Publication Date Title
JP5540101B2 (ja) ベンゾオキサゼピンｐｉ３ｋ阻害剤化合物及び使用方法
JP5546636B2 (ja) ベンゾキセピンｐｉ３ｋ阻害剤化合物及び使用方法
AU2015252149B2 (en) Benzoxazepin PI3K inhibitor compounds and methods of use
HK1174629B (en) Benzoxazepin pi3k inhibitor compounds and methods of use
HK1211929B (en) Benzoxazepin pi3k inhibitor compounds and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131101

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20131101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131121

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20131122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140401

R150 Certificate of patent or registration of utility model

Ref document number: 5540101

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140501

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250